Status:
COMPLETED
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Lead Sponsor:
Santen Inc.
Collaborating Sponsors:
MacuSight, Inc.
Conditions:
Diabetic Macular Edema
Diabetic Retinopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
Eligibility Criteria
Inclusion
- Inclusion Criteria include but are not limited to:
- Diagnosed with diabetes mellitus
- Visual acuity of 20/40 to 20/200 in study eye
- Exclusion Criteria include but are not limited to:
- Any other ocular disease that could compromise vision in the study eye
- Intraocular surgery of the study eye within 90 days prior to study start
- Capsulotomy of the study eye within 30 days prior to study start
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00401115
Start Date
September 1 2006
End Date
June 1 2008
Last Update
July 26 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Consultants of Arizona
Phoenix, Arizona, United States, 85014
2
Texas Retina Associates
Arlington, Texas, United States, 76012